References
- Di Raimondo F, Azzaro MP, Palumbo G, et al Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800–805.
- Munshi N, Wilson CS, Penn J, et al Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density in bone marrow biopsies. Blood 1998;92(Suppl. 1): (Abstract 98).
- Rajkumar SV, Leong T, Roche PC, et al Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111–3116.
- Ribatti D, Vacca A, Nico B, et al Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999;79:451–455.
- Vacca A, Ribatti D, Presta M, et al Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064–3073.
- Gupta D, Treon SP, Shima Y, et al Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950–1961.
- Dankbar B, Padro T, Leo R, et al Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630–2636.
- Podar K, Tai YT, Davies FE, et al Vascular endothelial growth factor (VEGF) triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428–435.
- Podar K, Tai YT, Lin BK, et al Vascular endothelial growth factor (VEGF)-induced migration of multiple myeloma cells is associated with β1-integrin and PI3-kinase-dependent PKCα activation. J Biol Chem 2002;277:7875–7881.
- Kumar S, Gertz MA, Dispenzieri A, et al Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004;34:235–239.
- Aguayo A, Kantarjian H, Manshouri T, et al Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240–2245.
- Wood JM, Bold G, Buchdunger E, et al PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178–2189.
- Lin B, Podar K, Gupta D, et al The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002;62:5019–5026.
- Bladé J, Samson D, Reece D, et al Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115–1123.
- Vermeulen PB, Gasparini G, Fox SB, et al Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of valuation. Eur J Cancer 1996;32A:2474–2484.